SS Innovations International, Inc. has received regulatory approval for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka, and Kenya, marking a significant expansion into markets the company describes as underpenetrated. The approvals were granted by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos in Colombia, the Directorate General of Pharmaceutical Affairs and Drug Control in Oman, the National Medicines Regulatory Authority in Sri Lanka, and the Pharmacy and Poisons Board in Kenya between November 2025 and January 2026.
The company positions the SSi Mantra as a cost-advantaged, technologically advanced system designed to democratize access to robotic surgery. Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, stated the expansion aligns with the goal of decentralizing excellence in surgical robotic care in underserved regions while continuing to pursue regulatory pathways in established markets like the United States and European Union. The company anticipates U.S. Food and Drug Administration review of its 510(k) premarket notification by mid-2026 and believes it can obtain European Union CE marking certification in 2026.
With these latest approvals, the SSi Mantra is now cleared for use in eleven countries, including India, Ecuador, Guatemala, Indonesia, the Philippines, Ukraine, and the United Arab Emirates. As of December 31, 2025, the system had an installed base of 168 units across ten countries, with cumulative surgeries reaching 7,885. These procedures included 390 cardiac surgeries and 121 pediatric surgeries, and more than 150 telesurgeries have been performed using the platform.
The SSi Mantra system features modular robotic arms, an open-faced ergonomic surgeon command center, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models. An optional portable console, the SSi MantrAsana Tele Surgeon Console, enables telesurgery capabilities. The system utilizes over 40 types of robotic instruments supporting various specialties, including cardiac and pediatric surgery, and has been clinically validated in India in more than 100 different surgical procedures. Further company information is available at https://ssinnovations.com.
For business and technology leaders, this expansion signals a shift in the global surgical robotics landscape, traditionally dominated by high-cost systems. By targeting cost-sensitive and underserved markets with an advanced yet affordable platform, SS Innovations could accelerate the adoption of minimally invasive robotic procedures in regions with limited access. This has implications for healthcare infrastructure development, surgical training, and patient outcomes in these countries. The company's progress in telesurgery also points to future models of remote surgical care and collaboration. As regulatory milestones in major markets approach, the competitive dynamics in the multi-billion dollar surgical robotics industry may intensify, potentially driving further innovation and cost considerations.
